Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Greene

Showing results (321-330 of 410) with videos related to

Pageof 41
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 3, 2013
Objectives and design of the hemodialysis fistula maturation studyLaura M Dember, Peter B Imrey, Gerald J Beck, et al.
Journal of the American Society of Nephrology : JASN|July 16, 2017
Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation StudyAlfred K Cheung, Peter B Imrey, Charles E Alpers, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
The rationale and design of the AASK cohort studyLawrence J Appel, John Middleton, Edgar R Miller, et al.
JAMA Network Open|October 13, 2025
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 DiabetesCatherine G Derington, Amara Sarwal, Guo Wei, et al.
Contemporary Clinical Trials|November 28, 2024
The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney diseaseJesse C Christensen, Shuchi Anand, Glenn M Chertow, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Kidney International|September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
JAMA|November 21, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJackson T Wright, George Bakris, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|July 12, 2019
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical SimulationTom Greene, Jian Ying, Edward F Vonesh, et al.
Circulation. Cardiovascular Imaging|February 25, 2012
Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) TrialsChristopher T Chan, Tom Greene, Glenn M Chertow, et al.
Pageof 41

Showing results (321-330 of 410) with videos related to

Sort By:
Pageof 41
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 3, 2013
Objectives and design of the hemodialysis fistula maturation studyLaura M Dember, Peter B Imrey, Gerald J Beck, et al.
Journal of the American Society of Nephrology : JASN|July 16, 2017
Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation StudyAlfred K Cheung, Peter B Imrey, Charles E Alpers, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
The rationale and design of the AASK cohort studyLawrence J Appel, John Middleton, Edgar R Miller, et al.
JAMA Network Open|October 13, 2025
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 DiabetesCatherine G Derington, Amara Sarwal, Guo Wei, et al.
Contemporary Clinical Trials|November 28, 2024
The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney diseaseJesse C Christensen, Shuchi Anand, Glenn M Chertow, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Kidney International|September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
JAMA|November 21, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJackson T Wright, George Bakris, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|July 12, 2019
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical SimulationTom Greene, Jian Ying, Edward F Vonesh, et al.
Circulation. Cardiovascular Imaging|February 25, 2012
Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) TrialsChristopher T Chan, Tom Greene, Glenn M Chertow, et al.
Pageof 41